Intended Audience: All neonatal nurses NCC Category Codes: NIC 1, NNP 3
Objectives: Upon completion, learners will be able to:
Differentiate advantages and disadvantages of various biological matrices used for neonatal substance exposure screening.
Discuss the legal implications of screening neonates for drug exposure.
Purpose of this CNE Activity: The purpose of this article is to provide an overview of the prevalence of gestational substance exposure, describe biologic matrices for neonatal drug screening, and briefly discuss the legal implications of neonatal drug screening.
Requirements for Completion: The following requirements are necessary for successful completion of this CNE activity.
Access to a computer with an Internet connection
Pass the posttest with a score of 80%
Complete and submit the evaluation for this CNE activity
Accreditation Provider, Academy of Neonatal Nursing, approved by the California Board of Registered Nursing, Provider #CEP 6261; and Florida Board of Nursing, Provider #FBN 3218, content code 2505.
The Academy of Neonatal Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Release Date: September/October 2016 Review Date: September 2019 Expiration Date: October 31, 2021
This CNE activity has been reviewed by the Lead Nurse Planner. It has been determined that the material presented here shows no bias.
The content of this CNE activity has been developed by the planning committee and has been reviewed by the Lead Nurse Planner.
Disclaimer: The Academy of Neonatal Nursing assumes no responsibility or liability for the content presented. Care of the infant should always be individualized and no one source relied upon for information regarding aspects of care. Accredited status does not imply endorsement by ANN, ANA, or the American Nurses Credentialing Center of any commercial products displayed or discussed in conjunction with an educational activity.